Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

British Journal of Haematology

Volumn 172, Issue 5, 2016, Pages 685-698

  Atanackovic, Djordje ^a   Radhakrishnan, Sabarinath V ^a   Bhardwaj, Neelam ^a   Luetkens, Tim ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Chimeric antigen receptors; Immunotherapy; Multiple myeloma; Tumour immunology

Indexed keywords

B CELL MATURATION ANTIGEN; CD200 ANTIGEN; CD229 ANTIGEN; CD307 ANTIGEN; CD317 ANTIGEN; CD319 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD47 ANTIGEN; CD56 ANTIGEN; CD74 ANTIGEN; CD81 ANTIGEN; CD86 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN; SOMATOMEDIN C RECEPTOR; SYNDECAN 1; UNCLASSIFIED DRUG; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL THERAPY; CLINICAL EFFECTIVENESS; DONOR LYMPHOCYTE INFUSION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; GENE THERAPY; GENETIC ENGINEERING; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION;

GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84958899793     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13889     Document Type: Review

References (146)

1. Abate-Daga, D., Hanada, K., Davis, J.L., Yang, J.C., Rosenberg, S.A. & Morgan, R.A. (2013) Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood, 122, 1399-1410.
2. Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H. & Honjo, T. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International Immunology, 8, 765-772.
3. Ahsmann, E.J., Lokhorst, H.M., Dekker, A.W. & Bloem, A.C. (1992) Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood, 79, 2068-2075.
4. Alizadeh, D., Trad, M., Hanke, N.T., Larmonier, C.B., Janikashvili, N., Bonnotte, B., Katsanis, E. & Larmonier, N. (2014) Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Research, 74, 104-118.
5. Atanackovic, D., Panse, J., Hildebrandt, Y., Jadczak, A., Kobold, S., Cao, Y., Templin, J., Meyer, S., Reinhard, H., Bartels, K., Lajmi, N., Zander, A.R., Marx, A.H., Bokemeyer, C. & Kroger, N. (2011) Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica, 96, 1512-1520.
6. Atanackovic, D., Luetkens, T. & Kroger, N. (2014) Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia, 28, 993-1000.
7. Barclay, A.N., Wright, G.J., Brooke, G. & Brown, M.H. (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends in Immunology, 23, 285-290.
8. Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G.J. & Crowley, J. (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood, 124, 3043-3051.
9. Barrena, S., Almeida, J., Yunta, M., Lopez, A., Fernandez-Mosteirin, N., Giralt, M., Romero, M., Perdiguer, L., Delgado, M., Orfao, A. & Lazo, P.A. (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia, 19, 1376-1383.
10. Bataille, R., Robillard, N., Avet-Loiseau, H., Harousseau, J.L. & Moreau, P. (2005) CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica, 90, 706-707.
11. Beatty, G.L., Torigian, D.A., Chiorean, E.G., Saboury, B., Brothers, A., Alavi, A., Troxel, A.B., Sun, W., Teitelbaum, U.R., Vonderheide, R.H. & O'Dwyer, P.J. (2013) A phase I study of an agonist CD40 monoclonal antibody (CP-870, 893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clinical Cancer Research, 19, 6286-6295.
12. Benjamin, R, Condomines, M, Gunset, G & Sadelain, M (2012) CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 72(Suppl. 8), 3499.
13. Bensinger, W., Maziarz, R.T., Jagannath, S., Spencer, A., Durrant, S., Becker, P.S., Ewald, B., Bilic, S., Rediske, J., Baeck, J. & Stadtmauer, E.A. (2012) A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 159, 58-66.
14. Benson, D.M. Jr, Bakan, C.E., Mishra, A., Hofmeister, C.C., Efebera, Y., Becknell, B., Baiocchi, R.A., Zhang, J., Yu, J., Smith, M.K., Greenfield, C.N., Porcu, P., Devine, S.M., Rotem-Yehudar, R., Lozanski, G., Byrd, J.C. & Caligiuri, M.A. (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood, 116, 2286-2294.
15. Besser, M.J., Shapira-Frommer, R., Itzhaki, O., Treves, A.J., Zippel, D.B., Levy, D., Kubi, A., Shoshani, N., Zikich, D., Ohayon, Y., Ohayon, D., Shalmon, B., Markel, G., Yerushalmi, R., Apter, S., Ben-Nun, A., Ben-Ami, E., Shimoni, A., Nagler, A. & Schachter, J. (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clinical Cancer Research, 19, 4792-4800.
16. Beyer, M., Kochanek, M., Giese, T., Endl, E., Weihrauch, M.R., Knolle, P.A., Classen, S. & Schultze, J.L. (2006) In vivo peripheral expansion of naive CD4 + CD25high FoxP3 + regulatory T cells in patients with multiple myeloma. Blood, 107, 3940-3949.
17. Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., De Rosa, L., Majolino, I., Novarese, L., Rocci, A., Gambella, M., Ciciarello, M., Scambia, G., Palumbo, A., Locatelli, F., De Cristofaro, R. & Rutella, S. (2012) Indoleamine 2, 3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine, 10, 247.
18. Brown, R., Kabani, K., Favaloro, J., Yang, S., Ho, P.J., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D. & Joshua, D. (2012) CD86 + or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood, 120, 2055-2063.
19. Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P.J., Iland, H., Fromm, P., Woodland, N., Nassif, N., Hart, D. & Joshua, D.E. (2013) Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, e148.
20. Burton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. & Goldenberg, D.M. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 6606-6611.
21. Byrd, J.C., Kipps, T.J., Flinn, I.W., Cooper, M., Odenike, O., Bendiske, J., Rediske, J., Bilic, S., Dey, J., Baeck, J. & O'Brien, S. (2012) Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukaemia & Lymphoma, 53, 2136-2142.
22. Carpenter, R.O., Evbuomwan, M.O., Pittaluga, S., Rose, J.J., Raffeld, M., Yang, S., Gress, R.E., Hakim, F.T. & Kochenderfer, J.N. (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research, 19, 2048-2060.
23. Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., Marcatti, M., Saudemont, A., Bordignon, C., Savoldo, B., Ciceri, F., Naldini, L., Dotti, G., Bonini, C. & Bondanza, A. (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood, 122, 3461-3472.
24. Chaidos, A., Barnes, C.P., Cowan, G., May, P.C., Melo, V., Hatjiharissi, E., Papaioannou, M., Harrington, H., Doolittle, H., Terpos, E., Dimopoulos, M., Abdalla, S., Yarranton, H., Naresh, K., Foroni, L., Reid, A., Rahemtulla, A., Stumpf, M., Roberts, I. & Karadimitris, A. (2013) Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 121, 318-328.
25. Chu, J., Deng, Y., Benson, D.M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., He, X., Devine, S.M., Zhang, X., Caligiuri, M.A., Hofmeister, C.C. & Yu, J. (2014a) CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia, 28, 917-927.
26. Chu, J., He, S., Deng, Y., Zhang, J., Peng, Y., Hughes, T., Yi, L., Kwon, C.H., Wang, Q.E., Devine, S.M., He, X., Bai, X.F., Hofmeister, C.C. & Yu, J. (2014b) Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clinical Cancer Research, 20, 3989-4000.
27. Claesson, L., Larhammar, D., Rask, L. & Peterson, P.A. (1983) cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proceedings of the National Academy of Sciences of the United States of America, 80, 7395-7399.
28. Deckert, J., Wetzel, M.C., Bartle, L.M., Skaletskaya, A., Goldmacher, V.S., Vallee, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., Dumontet, C., Plesa, A., Chiron, M., Lejeune, P., Chittenden, T., Park, P.U. & Blanc, V. (2014) SAR650984, a novel humanized cd38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38 + hematologic malignancies. Clinical Cancer Research, 20, 4574-4583.
29. Dhodapkar, M.V., Kelly, T., Theus, A., Athota, A.B., Barlogie, B. & Sanderson, R.D. (1997) Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. British Journal of Haematology, 99, 368-371.
30. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., Lennon, V.A., Celis, E. & Chen, L. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine, 8, 793-800.
31. Drach, J., Gattringer, C. & Huber, H. (1990) Multiple myeloma with coexpression of myeloid and natural killer cell antigens. Blood, 76, 265-266.
32. Dudley, M.E. & Rosenberg, S.A. (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Reviews Cancer, 3, 666-675.
33. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F., Wunderlich, J., Restifo, N.P., Thomasian, A., Downey, S.G., Smith, F.O., Klapper, J., Morton, K., Laurencot, C., White, D.E. & Rosenberg, S.A. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology, 26, 5233-5239.
34. Elkins, K., Zheng, B., Go, M., Slaga, D., Du, C., Scales, S.J., Yu, S.F., McBride, J., de Tute, R., Rawstron, A., Jack, A.S., Ebens, A. & Polson, A.G. (2012) FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Molecular Cancer Therapeutics, 11, 2222-2232.
35. Elsawa, S.F., Novak, A.J., Grote, D.M., Ziesmer, S.C., Witzig, T.E., Kyle, R.A., Dillon, S.R., Harder, B., Gross, J.A. & Ansell, S.M. (2006) B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood, 107, 2882-2888.
36. Fedorov, V.D., Themeli, M. & Sadelain, M. (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 5, 215ra172.
37. Forastiere, A.A., Zhang, Q., Weber, R.S., Maor, M.H., Goepfert, H., Pajak, T.F., Morrison, W., Glisson, B., Trotti, A., Ridge, J.A., Thorstad, W., Wagner, H., Ensley, J.F. & Cooper, J.S. (2012) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. Journal of Clinical Oncology, 26, 26.
38. Francisco, J.A., Gawlak, S.L. & Siegall, C.B. (1997) Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. Journal of Biological Chemistry, 272, 24165-24169.
39. Francisco, J.A., Donaldson, K.L., Chace, D., Siegall, C.B. & Wahl, A.F. (2000) Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Research, 60, 3225-3231.
40. Garfall, A.L., Maus, M.V., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Zheng, Z., Vogl, D.T., Cohen, A.D., Weiss, B.M., Dengel, K., Kerr, N.D.S., Hwang, W.T., Levine, B., June, C.H. & E.A ., S. (2015) Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. Journal of Clinical Oncology, 33, 8517.
41. Gargett, T. & Brown, M.P. (2014) The inducible caspase-9 suicide gene system as a 'safety switch' to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology, 5, 235.
42. Gorgun, G.T., Whitehill, G., Anderson, J.L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N.C., Richardson, P.G. & Anderson, K.C. (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood, 121, 2975-2987.
43. Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S.E., Frigault, M.J., Lee, J., Posey, A.D. Jr, Scholler, J., Scholler, N., Bonneau, R. & June, C.H. (2014) ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood, 124, 1070-1080.
44. de Haart, S.J., van de Donk, N.W., Minnema, M.C., Huang, J.H., Aarts-Riemens, T., Bovenschen, N., Yuan, H., Groen, R.W., McMillin, D.W., Jakubikova, J., Lokhorst, H.M., Martens, A.C., Mitsiades, C.S. & Mutis, T. (2013) Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clinical Cancer Research, 19, 5591-5601.
45. Hamilton, M.S., Ball, J., Bromidge, E. & Franklin, I.M. (1991) Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. British Journal of Haematology, 78, 60-65.
46. Harada, T., Ozaki, S., Oda, A., Tsuji, D., Ikegame, A., Iwasa, M., Udaka, K., Fujii, S., Nakamura, S., Miki, H., Kagawa, K., Kuroda, Y., Kawai, S., Itoh, K., Yamada-Okabe, H., Matsumoto, T. & Abe, M. (2013) Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. PLoS ONE, 8, e83905.
47. Hato, S.V., Khong, A., de Vries, I.J. & Lesterhuis, W.J. (2014) Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clinical Cancer Research, 20, 2831-2837.
48. Hayashi, T., Treon, S.P., Hideshima, T., Tai, Y.T., Akiyama, M., Richardson, P., Chauhan, D., Grewal, I.S. & Anderson, K.C. (2003) Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology, 121, 592-596.
49. Heffner, L.T., Jagannath, S., Zimmerman, T.M., Lee, K.P., Rosenblatt, J., Lonial, S., Lutz, R.J., Czeloth, N., Osterroth, F., Ruehle, M., Beelitz, M., Wartenberg-Demand, A., Haeder, T., Anderson, K.C. & Munshi, N.C. (2012) BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood, 120, 4042.
50. Hock, B.D., Drayson, M., Patton, W.N., Taylor, K., Kerr, L. & McKenzie, J.L. (2006) Circulating levels and clinical significance of soluble CD86 in myeloma patients. British Journal of Haematology, 133, 165-172.
51. Hsi, E.D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B.P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A.G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, J.D. Jr, Barlogie, B., van Rhee, F., Hussein, M., Afar, D.E. & Williams, M.B. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research, 14, 2775-2784.
52. Huang, Y.W., Richardson, J.A. & Vitetta, E.S. (1995) Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Research, 55, 610-616.
53. Hussein, M., Berenson, J.R., Niesvizky, R., Munshi, N., Matous, J., Sobecks, R., Harrop, K., Drachman, J.G. & Whiting, N. (2010) A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica, 95, 845-848.
54. Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R.J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.T., Cirstea, D., Raje, N.S., Uherek, C., Dalken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P. & Anderson, K.C. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clinical Cancer Research, 15, 4028-4037.
55. Ise, T., Nagata, S., Kreitman, R.J., Wilson, W.H., Wayne, A.S., Stetler-Stevenson, M., Bishop, M.R., Scheinberg, D.A., Rassenti, L., Kipps, T.J., Kyle, R.A., Jelinek, D.F. & Pastan, I. (2007) Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia, 21, 169-174.
56. Janossy, G., Tidman, N., Papageorgiou, E.S., Kung, P.C. & Goldstein, G. (1981) Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. The Journal of Immunology : Official Journal of the American Association of Immunologists, 126, 1608-1613.
57. Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., Man-Yuen Sze, D., Yi, Q. & Hou, J. (2014) Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular Oncology, 8, 297-310.
58. John, L.B., Devaud, C., Duong, C.M., Yong, C., Beavis, P.A., Haynes, N.M., Chow, M.T., Smyth, M.J., Kershaw, M.H. & Darcy, P.K. (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinical Cancer Research, 19, 5636-5646.
59. Karyampudi, L., Lamichhane, P., Scheid, A.D., Kalli, K.R., Shreeder, B., Krempski, J.W., Behrens, M.D. & Knutson, K.L. (2014) Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Research, 74, 2974-2985.
60. Kaufman, J.L., Niesvizky, R., Stadtmauer, E.A., Chanan-Khan, A., Siegel, D., Horne, H., Wegener, W.A. & Goldenberg, D.M. (2013) Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British Journal of Haematology, 163, 478-486.
61. Kelly, K.R., Chanan-Khan, A., Heffner, L.T., Somlo, G., Siegel, D.S., Zimmerman, T., Karnad, A., Munshi, N.C., Jagannath, S., Greenberg, A., Lonial, S., Roy, V., Ailawadhi, S., Barmaki-Rad, F., Chavan, S., Patel, P., Wartenberg-Demand, A., Haeder, T. & Anderson, K.C. (2014) Indatuximab Ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to Lenalidomide and Bortezomib. Blood, 124, 4736.
62. Kerkar, S.P. & Restifo, N.P. (2012) Cellular constituents of immune escape within the tumor microenvironment. Cancer Research, 72, 3125-3130.
63. Kim, D., Wang, J., Willingham, S.B., Martin, R., Wernig, G. & Weissman, I.L. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia, 26, 2538-2545.
64. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 31, 71-75.
65. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., Yang, J.C., Kammula, U.S., Devillier, L., Carpenter, R., Nathan, D.A., Morgan, R.A., Laurencot, C. & Rosenberg, S.A. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 119, 2709-2720.
66. Kretz-Rommel, A., Qin, F., Dakappagari, N., Cofiell, R., Faas, S.J. & Bowdish, K.S. (2008) Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. The Journal of Immunology : Official Journal of the American Association of Immunologists, 180, 699-705.
67. Kroger, N. (2007) Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia, 21, 1851-1858.
68. Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., Buadi, F.K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S.R., Leung, N., Lust, J., McCurdy, A., Russell, S.J., Zeldenrust, S.R., Kyle, R.A. & Rajkumar, S.V. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 28, 1122-1128.
69. Kwong, M.L., Neyns, B. & Yang, J.C. (2013) Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clinical Cancer Research, 19, 5292-5299.
70. Laabi, Y., Gras, M.P., Brouet, J.C., Berger, R., Larsen, C.J. & Tsapis, A. (1994) The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Research, 22, 1147-1154.
71. Larson, D.F. & Horak, K. (2006) Macrophage migration inhibitory factor: controller of systemic inflammation. Critical Care, 10, 138.
72. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A. & Mackall, C.L. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124, 188-195.
73. Lin, P., Owens, R., Tricot, G. & Wilson, C.S. (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology, 121, 482-488.
74. Liu, Y., Wang, L., Predina, J., Han, R., Beier, U.H., Wang, L.C., Kapoor, V., Bhatti, T.R., Akimova, T., Singhal, S., Brindle, P.K., Cole, P.A., Albelda, S.M. & Hancock, W.W. (2013) Inhibition of p300 impairs Foxp3(+) T regulatory cell function and promotes antitumor immunity. Nature Medicine, 19, 1173-1177.
75. Lokhorst, H., Einsele, H., Vesole, D., Bruno, B., San Miguel, J., Perez-Simon, J.A., Kroger, N., Moreau, P., Gahrton, G., Gasparetto, C., Giralt, S. & Bensinger, W. (2010) International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. Journal of Clinical Oncology, 28, 4521-4530.
76. Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M.C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N.W., Ahmadi, T., Khan, I., Uhlar, C.M., Wang, J., Sasser, A.K., Losic, N., Lisby, S., Basse, L., Brun, N. & Richardson, P.G. (2015) Targeting CD38 with Daratumumab monotherapy in multiple myeloma. New England Journal of Medicine, 373, 1207-1219.
77. Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Rollig, C., Einsele, H., Wu, K.L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K.C. & Richardson, P. & Elotuzumab Investigators. (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 373, 621-631.
78. Luo, R.F., Zhao, S., Tibshirani, R., Myklebust, J.H., Sanyal, M., Fernandez, R., Gratzinger, D., Marinelli, R.J., Lu, Z.S., Wong, A., Levy, R., Levy, S. & Natkunam, Y. (2010) CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Human Pathology, 41, 271-280.
79. Martin, T.G., Strickland, S.A., Glenn, M., Zheng, W., Daskalakis, N. & Mikhael, J.R. (2013) SAR650984, A CD38 monoclonal antibody in patients with selected CD38 + hematological malignancies - data from a dose-escalation Phase I study. Blood (ASH Annual Meeting Abstracts), 122, 284.
80. Martin, T.G., Baz, R., Benson, D.M., Lendvai, N., Campana, F., Charpentier, E. & Vij, R. (2014) A Phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with Lenalidomide and Dexamethasone in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 124, 83.
81. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L. & Grupp, S.A. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371, 1507-1517.
82. Mawby, W.J., Holmes, C.H., Anstee, D.J., Spring, F.A. & Tanner, M.J. (1994) Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. The Biochemical Journal, 304, 525-530.
83. Mihara, K., Yanagihara, K., Takigahira, M., Imai, C., Kitanaka, A., Takihara, Y. & Kimura, A. (2009) Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. Journal of Immunotherapy, 32, 737-743.
84. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T.A., Garcia-Echeverria, C., Pearson, M.A., Hofmann, F., Anderson, K.C. & Kung, A.L. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell, 5, 221-230.
85. Mok, S., Koya, R.C., Tsui, C., Xu, J., Robert, L., Wu, L., Graeber, T.G., West, B.L., Bollag, G. & Ribas, A. (2014) Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Research, 74, 153-161.
86. Moreau, P., Cavallo, F., Leleu, X., Hulin, C., Amiot, M., Descamps, G., Facon, T., Boccadoro, M., Mignard, D. & Harousseau, J.L. (2011) Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia, 25, 872-874.
87. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J.F., Klein, B. & Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 3148-3157.
88. Moreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P., Bourin, P., Moos, M., Corre, J., Mohler, T., De Vos, J., Rossi, J.F., Goldschmidt, H. & Klein, B. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood, 108, 4194-4197.
89. Noonan, K.A., Ghosh, N., Rudraraju, L., Bui, M. & Borrello, I. (2014) Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunology Research, 2, 725-731.
90. Oki, Y., Buglio, D., Zhang, J., Ying, Y., Zhou, S., Sureda, A., Ben-Yehuda, D., Zinzani, P.L., Prince, H.M., Harrison, S.J., Kirschbaum, M., Johnston, P.B., Shen, A., von Tresckow, B. & Younes, A. (2014) Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer Journal, 4, e236.
91. Ortaldo, J.R., Sharrow, S.O., Timonen, T. & Herberman, R.B. (1981) Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. The Journal of Immunology : Official Journal of the American Association of Immunologists, 127, 2401-2409.
92. Ozaki, S., Kosaka, M., Wakatsuki, S., Abe, M., Koishihara, Y. & Matsumoto, T. (1997) Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood, 90, 3179-3186.
93. Paiva, B., Gutierrez, N.C., Chen, X., Vidriales, M.B., Montalban, M.A., Rosinol, L., Oriol, A., Martinez-Lopez, J., Mateos, M.V., Lopez-Corral, L., Diaz-Rodriguez, E., Perez, J.J., Fernandez-Redondo, E., de Arriba, F., Palomera, L., Bengoechea, E., Terol, M.J., de Paz, R., Martin, A., Hernandez, J., Orfao, A., Lahuerta, J.J., Blade, J., Pandiella, A., Miguel, J.F. & GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative (2012) Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia, 26, 1862-1869.
94. Palumbo, A. & Anderson, K. (2011) Multiple myeloma. New England Journal of Medicine, 364, 1046-1060.
95. Pellat-Deceunynck, C., Barille, S., Puthier, D., Rapp, M.J., Harousseau, J.L., Bataille, R. & Amiot, M. (1995) Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Research, 55, 3647-3653.
96. Perez-Andres, M., Almeida, J., Martin-Ayuso, M., Moro, M.J., Martin-Nunez, G., Galende, J., Borrego, D., Rodriguez, M.J., Ortega, F., Hernandez, J., Moreno, I., Dominguez, M., Mateo, G., San Miguel, J.F. & Orfao, A., Spanish Network on multiple myeloma (G03/136); Spanish Network of Cancer Research Centers (C03/10). (2005) Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia, 19, 449-455.
97. Perna, S.K., Pagliara, D., Mahendravada, A., Liu, H., Brenner, M.K., Savoldo, B. & Dotti, G. (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clinical Cancer Research, 20, 131-139.
98. Plesner, T., Arkenau, T., Lokhorst, H., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M.C., Lassen, U., Laubach, J.P., Ahmadi, T., Howard, Y., Guckert, M.E., Feng, H., Brun, N.C., Steen, L., Basse, L., Palumbo, A. & Richardson, P.G. (2014) Safety and efficacy of Daratumumab with Lenalidomide and Dexamethasone in relapsed or relapsed. Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 124, 84.
99. Pope, B., Brown, R.D., Gibson, J., Yuen, E. & Joshua, D. (2000) B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood, 96, 1274-1279.
100. Posner, M.R., Hershock, D.M., Blajman, C.R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D.M., Cullen, K., Ervin, T.J., Murphy, B.A., Raez, L.E., Cohen, R.B., Spaulding, M., Tishler, R.B., Roth, B., Viroglio Rdel, C., Venkatesan, V., Romanov, I., Agarwala, S., Harter, K.W., Dugan, M., Cmelak, A., Markoe, A.M., Read, P.W., Steinbrenner, L., Colevas, A.D., Norris, C.M. Jr & Haddad, R.I. (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. New England Journal of Medicine, 357, 1705-1715.
101. Purushothaman, A. & Toole, B.P. (2014) Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization. Journal of Biological Chemistry, 289, 5499-5509.
102. Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S.C., Rao, S.S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K.C., Roth, J., Yi, Q., Overwijk, W.W. & Kwak, L.W. (2014) Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine, 20, 676-681.
103. Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G. & Anderson, K.C. (2009) Multiple myeloma. Lancet, 374, 324-339.
104. Rawstron, A., Barrans, S., Blythe, D., Davies, F., English, A., Pratt, G., Child, A., Morgan, G. & Jack, A. (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. British Journal of Haematology, 104, 138-143.
105. Rawstron, A.C., Child, J.A., de Tute, R.M., Davies, F.E., Gregory, W.M., Bell, S.E., Szubert, A.J., Navarro-Coy, N., Drayson, M.T., Feyler, S., Ross, F.M., Cook, G., Jackson, G.H., Morgan, G.J. & Owen, R.G. (2013) Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology, 31, 2540-2547.
106. Reinherz, E.L., Kung, P.C., Goldstein, G., Levey, R.H. & Schlossman, S.F. (1980) Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proceedings of the National Academy of Sciences of the United States of America, 77, 1588-1592.
107. van Rhee, F., Szmania, S.M., Dillon, M., van Abbema, A.M., Li, X., Stone, M.K., Garg, T.K., Shi, J., Moreno-Bost, A.M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A.G., Zhan, F., Shaughnessy, J.D. Jr, Barlogie, B., Yaccoby, S. & Afar, D.E. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 8, 2616-2624.
108. Richardson, P.G., Schlossman, R.L., Alsina, M., Weber, D.M., Coutre, S.E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M.S., Khan, M., Paley, C.S. & Lonial, S. (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood, 122, 2331-2337.
109. Romano, A., Conticello, C., Cavalli, M., Vetro, C., La Fauci, A., Parrinello, N.L. & Di Raimondo, F. (2014) Immunological dysregulation in multiple myeloma microenvironment. BioMed Research International, 2014, 198539.
110. Sanchez, E., Li, M., Kitto, A., Li, J., Wang, C.S., Kirk, D.T., Yellin, O., Nichols, C.M., Dreyer, M.P., Ahles, C.P., Robinson, A., Madden, E., Waterman, G.N., Swift, R.A., Bonavida, B., Boccia, R., Vescio, R.A., Crowley, J., Chen, H. & Berenson, J.R. (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. British Journal of Haematology, 158, 727-738.
111. Sanderson, R.D., Turnbull, J.E., Gallagher, J.T. & Lander, A.D. (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. Journal of Biological Chemistry, 269, 13100-13106.
112. Sandrin, M.S., Henning, M.M., Lo, M.F., Baker, E., Sutherland, G.R. & McKenzie, I.F. (1996) Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9. Immunogenetics, 43, 13-19.
113. Schutt, P., Brandhorst, D., Stellberg, W., Poser, M., Ebeling, P., Muller, S., Buttkereit, U., Opalka, B., Lindemann, M., Grosse-Wilde, H., Seeber, S., Moritz, T. & Nowrousian, M.R. (2006) Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leukaemia & Lymphoma, 47, 1570-1582.
114. Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V. & Borrello, I. (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine, 203, 2691-2702.
115. Sieff, C., Bicknell, D., Caine, G., Robinson, J., Lam, G. & Greaves, M.F. (1982) Changes in cell surface antigen expression during hemopoietic differentiation. Blood, 60, 703-713.
116. Stein, R., Mattes, M.J., Cardillo, T.M., Hansen, H.J., Chang, C.H., Burton, J., Govindan, S. & Goldenberg, D.M. (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clinical Cancer Research, 13, 5556s-5563s.
117. Stevenson, F.K., Bell, A.J., Cusack, R., Hamblin, T.J., Slade, C.J., Spellerberg, M.B. & Stevenson, G.T. (1991) Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood, 77, 1071-1079.
118. Tai, Y.T., Podar, K., Mitsiades, N., Lin, B., Mitsiades, C., Gupta, D., Akiyama, M., Catley, L., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2003) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood, 101, 2762-2769.
119. Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weller, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. & Anderson, K.C. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 1329-1337.
120. Tai, Y.T., Mayes, P.A., Acharya, C., Zhong, M.Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., Hoang, B., Tunstead, J., Christie, A.L., Kung, A.L., Richardson, P., Munshi, N.C. & Anderson, K.C. (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 123, 3128-3138.
121. Tamura, H., Ishibashi, M., Yamashita, T., Tanosaki, S., Okuyama, N., Kondo, A., Hyodo, H., Shinya, E., Takahashi, H., Dong, H., Tamada, K., Chen, L., Dan, K. & Ogata, K. (2013) Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia, 27, 464-472.
122. Tangye, S.G., Phillips, J.H. & Lanier, L.L. (2000) The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. Seminars in Immunology, 12, 149-157.
123. Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. & Munshi, N.C. (2004) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56 + multiple myeloma cells. Cancer Research, 64, 4629-4636.
124. Terstappen, L.W., Johnsen, S., Segers-Nolten, I.M. & Loken, M.R. (1990) Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood, 76, 1739-1747.
125. Theocharis, A.D., Seidel, C., Borset, M., Dobra, K., Baykov, V., Labropoulou, V., Kanakis, I., Dalas, E., Karamanos, N.K., Sundan, A. & Hjerpe, A. (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. Journal of Biological Chemistry, 281, 35116-35128.
126. Tominaga, N., Katagiri, S., Ohnishi, M., Nakao, H., Oritani, K., Yagura, H., Tamaki, T., Kanayama, Y., Yonezawa, T. & Tarui, S. (1989) Analysis of surface antigen expression of human immunoglobulin-secreting cells: phenotypic heterogeneity in normal counterparts of myeloma cells. British Journal of Haematology, 73, 302-308.
127. Tong, A.W., Zhang, B.Q., Mues, G., Solano, M., Hanson, T. & Stone, M.J. (1994) Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood, 84, 3026-3033.
128. Van Camp, B., Thielemans, C., Dehou, M.F., De Mey, J. & De Waele, M. (1982) Two monoclonal antibodies (OKIa1 and OKT10) for the study of the final B cell maturation. Journal of Clinical Immunology, 2, 67S-74S.
129. Van Camp, B., Durie, B.G., Spier, C., De Waele, M., Van Riet, I., Vela, E., Frutiger, Y., Richter, L. & Grogan, T.M. (1990) Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood, 76, 377-382.
130. Van Riet, I., De Waele, M., Remels, L., Lacor, P., Schots, R. & Van Camp, B. (1991) Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. British Journal of Haematology, 79, 421-427.
131. Vekemans, M.C., Michaux, L., Van Den Neste, E. & Ferrant, A. (2014) Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma. British Journal of Haematology, 166, 616-618.
132. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G., Ludwig, H., Geley, S., Kofler, R. & Greil, R. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90, 12-20.
133. Vincent, T. & Mechti, N. (2004) IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia, 18, 967-975.
134. Vonderheide, R.H., Flaherty, K.T., Khalil, M., Stumacher, M.S., Bajor, D.L., Hutnick, N.A., Sullivan, P., Mahany, J.J., Gallagher, M., Kramer, A., Green, S.J., O'Dwyer, P.J., Running, K.L., Huhn, R.D. & Antonia, S.J. (2007) Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. Journal of Clinical Oncology, 25, 876-883.
135. de Weers, M., Tai, Y.T., van der Veer, M.S., Bakker, J.M., Vink, T., Jacobs, D.C., Oomen, L.A., Peipp, M., Valerius, T., Slootstra, J.W., Mutis, T., Bleeker, W.K., Anderson, K.C., Lokhorst, H.M., van de Winkel, J.G. & Parren, P.W. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. The Journal of Immunology : Official Journal of the American Association of Immunologists, 186, 1840-1848.
136. Westendorf, J.J., Ahmann, G.J., Armitage, R.J., Spriggs, M.K., Lust, J.A., Greipp, P.R., Katzmann, J.A. & Jelinek, D.F. (1994) CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. The Journal of Immunology : Official Journal of the American Association of Immunologists, 152, 117-128.
137. Wijdenes, J., Vooijs, W.C., Clement, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R.X., Klein, B. & Dore, J.M. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. British Journal of Haematology, 94, 318-323.
138. Wu, C.Y., Roybal, K.T., Puchner, E.M., Onuffer, J. & Lim, W.A. (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science, 350, aab4077.
139. Xu, S. & Lam, K.P. (2001) B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Molecular and Cellular Biology, 21, 4067-4074.
140. Yamashita, T., Tamura, H., Satoh, C., Shinya, E., Takahashi, H., Chen, L., Kondo, A., Tsuji, T., Dan, K. & Ogata, K. (2009) Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Clinical Cancer Research, 15, 770-777.
141. Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D.M., Okumura, K., Azuma, M. & Yagita, H. (2002) Expression of programmed death 1 ligands by murine T cells and APC. The Journal of Immunology : Official Journal of the American Association of Immunologists, 169, 5538-5545.
142. Yang, Y., Yaccoby, S., Liu, W., Langford, J.K., Pumphrey, C.Y., Theus, A., Epstein, J. & Sanderson, R.D. (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 100, 610-617.
143. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, J. Jr (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99, 1745-1757.
144. Zhu, Z., Singh, V., Watkins, S.K., Bronte, V., Shoe, J.L., Feigenbaum, L. & Hurwitz, A.A. (2013) High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Research, 73, 595-604.
145. Zismanov, V., Lishner, M., Tartakover-Matalon, S., Radnay, J., Shapiro, H. & Drucker, L. (2009) Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. British Journal of Cancer, 101, 1402-1409.
146. Zonder, J.A., Mohrbacher, A.F., Singhal, S., van Rhee, F., Bensinger, W.I., Ding, H., Fry, J., Afar, D.E. & Singhal, A.K. (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood, 120, 552-559.